Lixisenatide

Brand names: Soliqua 100/33 · Active ingredient: Lixisenatide

In short: SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: SOLIQUA 100/33 contains lixisenatide.

Forms & strengthsSOLIQUA 100/33 is a clear, colorless to almost colorless solution available as: Injection: 100 units of insulin glargine and 33 mcg of lixisenatide per mL in a 3 mL prefilled, disposable, single-patient-use SoloStar® pen.
LabelSanofi-Aventis U.S. LLC
Label updatedMar 20, 2026

What is Lixisenatide used for?

SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use:

SOLIQUA 100/33 contains lixisenatide. Coadministration with any other product containing lixisenatide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended .

SOLIQUA 100/33 is not recommended for the treatment of diabetic ketoacidosis.

SOLIQUA 100/33 has not been studied in combination with prandial insulin.

Lixisenatide dosage

SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide.

Administer SOLIQUA 100/33 subcutaneously once a day within the hour prior to the first meal of the day.

The SOLIQUA 100/33 pen delivers doses from 15 to 60 units in a single injection. Table 1 presents the units of insulin glargine and the micrograms of lixisenatide in each dosage of SOLIQUA 100/33 .

The maximum dose of SOLIQUA 100/33 is 60 units daily (60 units insulin glargine and 20 mcg lixisenatide) .

In patients naive to basal insulin or to a GLP-1 receptor agonist, currently on a GLP-1 receptor agonist or currently on less than 30 units of basal insulin daily:

Discontinue therapy with basal insulin or a GLP-1 receptor agonist prior to initiation of SOLIQUA 100/33.

The recommended starting dosage of SOLIQUA 100/33 is 15 units (15 units insulin glargine and 5 mcg lixisenatide) given subcutaneously once daily.

In patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 receptor agonist:

Discontinue therapy with basal insulin or GLP-1 receptor agonist prior to initiation of SOLIQUA 100/33.

The recommended starting dosage of SOLIQUA 100/33 is 30 units (30 units insulin glargine and 10 mcg lixisenatide) given subcutaneously once daily.

SOLIQUA 100/33(dose window display)The dose window on the SOLIQUA 100/33 pen displays numbers for the even units and displays lines for the odd units. | Insulin glargine component dose | Lixisenatide component dose | Comment

2 | --- | --- | Safety test dose – not for injection

15 | 15 units | 5 mcg | Recommended starting dosage for patients naive to basal insulin or GLP-1 receptor agonist, currently on GLP-1 receptor agonist, or currently on less than 30 units of basal insulin daily

16 | 16 units | 5.3 mcg

17 | 17 units | 5.7 mcg

18 | 18 units | 6 mcg

19 | 19 units | 6.3 mcg

20 | 20 units | 6.7 mcg

21 | 21 units | 7 mcg

22 | 22 units | 7.3 mcg

23 | 23 units | 7.7 mcg

24 | 24 units | 8 mcg

25 | 25 units | 8.3 mcg

26 | 26 units | 8.7 mcg

27 | 27 units | 9 mcg

28 | 28 units | 9.3 mcg

29 | 29 units | 9.7 mcg

30 | 30 units | 10 mcg | Recommended starting dosage for patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 receptor agonist:

31 | 31 units | 10.3 mcg

32 | 32 units | 10.7 mcg

33 | 33 units | 11 mcg

34 | 34 units | 11.3 mcg

35 | 35 units | 11.7 mcg

36 | 36 units | 12 mcg

37 | 37 units | 12.3 mcg

38 | 38 units | 12.7 mcg

39 | 39 units | 13 mcg

40 | 40 units | 13.3 mcg

41 | 41 units | 13.7 mcg

42 | 42 units | 14 mcg

43 | 43 units | 14.3 mcg

44 | 44 units | 14.7 mcg

45 | 45 units | 15 mcg

46 | 46 units | 15.3 mcg

47 | 47 units | 15.7 mcg

48 | 48 units | 16 mcg

49 | 49 units | 16.3 mcg

50 | 50 units | 16.7 mcg

51 | 51 units | 17 mcg

52 | 52 units | 17.3 mcg

53 | 53 units | 17.7 mcg

54 | 54 …

How to take Lixisenatide — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Anaphylaxis and Serious Hypersensitivity Reactions

Inform patients that serious hypersensitivity reactions, including anaphylaxis, have been reported with SOLIQUA 100/33. If symptoms of hypersensitivity reactions occur, instruct patients to stop taking SOLIQUA 100/33 and seek medical advice promptly .

Acute Pancreatitis

Inform patients of the potential risk for acute pancreatitis and its symptoms: severe abdominal pain that may radiate to the back, and which may or may not be accompanied by nausea or vomiting. Instruct patients to discontinue SOLIQUA 100/33 promptly and contact their physician if pancreatitis is suspected .

Never Share SOLIQUA 100/33 Prefilled Pen Between Patients

Advise patients that they must never share a SOLIQUA 100/33 prefilled pen with another person, even if the needle is changed because doing so carries a risk for transmission of blood-borne pathogens .

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen

Inform patients that hypoglycemia is the most common adverse reaction with insulin-containing products. …

Warnings & precautions

Do not take this medicine if: SOLIQUA 100/33 is contraindicated:

During episodes of hypoglycemia .

In patients with serious hypersensitivity to insulin glargine, lixisenatide, or any of the excipients in SOLIQUA 100/33. Hypersensitivity reactions including anaphylaxis have occurred with both lixisenatide and insulin glargine .

In clinical trials of lixisenatide there have been cases of anaphylaxis (frequency of 0.1% or 10 cases per 10,000 patient-years) and other serious hypersensitivity reactions including angioedema. Severe, life-threatening, generalized allergic reactions, including anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, and shock can occur with insulins, including insulin glargine. There have been postmarketing reports of serious hypersensitivity reactions, including anaphylactic reactions and angioedema, in patients treated with SOLIQUA 100/33 .

Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with SOLIQUA 100/33. SOLIQUA 100/33 is contraindicated in patients with known serious hypersensitivity to lixisenatide or insulin glargine . If a hypersensitivity reaction occurs, the patient should discontinue SOLIQUA 100/33 and promptly seek medical attention.

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists .

After initiation of SOLIQUA 100/33, observe patients carefully for signs and symptoms of acute pancreatitis which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue SOLIQUA 100/33 and initiate appropriate management. …

Lixisenatide side effects

The following adverse reactions are discussed elsewhere:

Anaphylaxis and Serious Hypersensitivity Reactions

Acute Pancreatitis

Hypoglycemia

Acute Kidney Injury Due to Volume Depletion

Severe Gastrointestinal Adverse Reactions

Hypokalemia

Acute Gallbladder Disease

Pulmonary Aspiration During General Anesthesia or Deep Sedation

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

The safety of SOLIQUA 100/33 (n=834, with a mean treatment duration of 203 days) has been evaluated in two clinical studies (30 weeks duration) in type 2 diabetes patients. The studies, Study A and B , had the following characteristics: mean age was approximately 59 years; approximately 50% were male, 90% were Caucasian, 6% were Black or African American, and 18% were Hispanic. The mean duration of diabetes was 10.3 years, mean HbA1c at screening for Study A was 8.2 and Study B was 8.5. The mean BMI at baseline was 32 kg/m2. Baseline eGFR was ≥60 mL/min in 87.2% of the pooled study population and mean baseline eGFR was 83.0 mL/min/1.73 m2. …

Drug interactions

A number of medications affect glucose metabolism and may require dose adjustment of SOLIQUA 100/33 and particularly close monitoring.

Drugs That May Increase the Risk of Hypoglycemia

Drugs: | Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.

Intervention: | Dose reductions and increased frequency of glucose monitoring may be required when SOLIQUA 100/33 is coadministered with these drugs.

Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33

Drugs: | Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.

Intervention: | Dose increases and increased frequency of glucose monitoring may be required when SOLIQUA 100/33 is coadministered with these drugs. …

About this medicine

SOLIQUA 100/33 is a combination of insulin glargine, an insulin analog, and lixisenatide, a GLP-1 receptor agonist.

Insulin glargine is a human insulin analog produced by recombinant DNA technology utilizing a nonpathogenic laboratory strain of Escherichia coli (K12) as the production organism. The minimum potency of insulin glargine is NLT 15 units/mg. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added at the C-terminus of the B-chain. Insulin glargine has low aqueous solubility at neutral pH. At pH 4 insulin glargine is completely soluble. It has a molecular weight of 6.063 kDa.

Lixisenatide is a synthetic analogue of human GLP-1, which acts as a GLP-1 receptor agonist. Lixisenatide is a protein containing 44 amino acids, which is amidated at the C-terminal amino acid (position 44) and has a molecular weight of 4.8585 kDa.

SOLIQUA 100/33 (insulin glargine and lixisenatide) injection is a sterile, colorless to almost colorless solution for subcutaneous use. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc. Read the full official label on DailyMed.

Related medicines

Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro